Previous Close | 11.94 |
Open | 11.87 |
Bid | 12.00 x 3100 |
Ask | 12.06 x 3000 |
Day's Range | 11.72 - 11.94 |
52 Week Range | 8.74 - 13.62 |
Volume | |
Avg. Volume | 10,355,431 |
Market Cap | 13.966B |
Beta (5Y Monthly) | 1.14 |
PE Ratio (TTM) | 235.20 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.48 (4.08%) |
Ex-Dividend Date | Mar 08, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for VTRS
Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1]
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Idorsia Ltd (SIX: IDIA) today announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full-year 2023 financial results Wednesday, Feb. 28, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.